Danish drugmaker Lundbeck has announced to acquire US company Longboard Pharmaceuticals in a deal valued at approximately $2.6 billion. Longboard, headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases.
Under the terms of the agreement, Lundbeck will make a tender offer for all outstanding shares of Longboard common stock, offering to pay Longboard shareholders $60.00 per share in cash.
The board of directors of both companies have unanimously approved the transaction, which is expected to close in the fourth quarter of 2024.
Through the acquisition of Longboard, Lundbeck gains access to bexicaserin, a novel 5-HT2C agonist in development for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies. Bexicaserin has shown encouraging anti-seizure reduction in preclinical and clinical studies and is now being evaluated in a global Phase III clinical program.
Source: chemanager-online.com
Fresenius Kabi’s cell therapy processing technologies will be integrated into Cellular Origins’ Constellation robotic platform. The partnership’s primary objective is to streamline the production of cell therapies at scale, maintaining the use of developers’ preferred tools for processing.
Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), a US-based investment company, regarding the potential sale of a 50% controlling stake in its consumer healthcare business, Opella. The move marks a significant step in the company’s ongoing effort to sharpen its focus on its core areas of innovative medicines and vaccines.
Lotte Fine Chemical announced on Oct. 7 that it has entered into a global distribution agreement with Colorcon, the world’s leading distributor of pharmaceutical cellulose based in the USA. The agreement, valued at $1 billion, entails the sale of Lotte Fine Chemical’s high-value specialty pharmaceutical cellulose products through Colorcon in the global pharmaceutical market for the next 10 years.
